Zymeworks Shares Phase 1 Ovarian Cancer Trial Data
The company presented clinical results for its ZW191 therapy at the European Society for Medical Oncology Congress.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Should medical research focus more on developing new treatments for advanced, hard-to-treat diseases?
Zymeworks shared positive Phase 1 clinical trial data for its investigational cancer treatment, ZW191, at the ESMO Congress in Madrid. The study evaluated two different dose levels in 80 patients diagnosed with platinum-resistant ovarian cancer.
Why it matters
This clinical data release is intended to guide Zymeworks in identifying the optimal dose for further development of ZW191. The company is now exploring partnerships or strategic collaborations to advance the candidate into late-stage clinical trials.
In the study of 80 patients, the 6.4 mg/kg dose resulted in a 64.5% objective response rate, while the 9.6 mg/kg dose yielded 55.3%. Treatment-related adverse events of Grade 3 or higher were observed in 22% and 44% of patients, respectively.
The players
Zymeworks
A clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, focused on developing multifunctional biotherapeutics.
ESMO Congress
An annual international meeting organized by the European Society for Medical Oncology that gathers professionals to discuss cancer treatment innovations.
The details
The trial randomized patients with platinum-resistant ovarian cancer to receive doses every three weeks, with researchers assessing folate receptor alpha expression via immunohistochemistry. While efficacy was demonstrated at both levels, the median duration of response remains undetermined.
Timeline
September 10, 2026: The study data cutoff date.
October 24, 2026: Clinical data presentation at the ESMO Congress.
October 27, 2026: Public conference call regarding the findings.
The Big Picture
This trial follows the established industry trend for the development of folate receptor alpha-targeted therapies for gynecological malignancies. It marks a continued focus on identifying manageable toxicity profiles in antibody-drug conjugate treatments.
The results provide potential future treatment pathways for those with platinum-resistant ovarian cancer. Patients should discuss new clinical trial opportunities and emerging therapies with their specialized oncology care teams.
The takeaway
This Phase 1 data highlights the efficacy and safety profile of ZW191 in a difficult-to-treat cancer population. Future advancements will depend on the company securing the necessary collaborative support to move into larger clinical studies.
Further reading
Learn more about the latest breakthroughs in clinical oncology by visiting our Cancer section.
More information
View the Zymeworks investor conference call details for additional information.
Live Poll
Should medical research focus more on developing new treatments for advanced, hard-to-treat diseases?
